Positive topline results from study of ABT 450/r, ABT 267, ABT 333 (Abbott) for Hepatitis C

Abbott announced topline results from AVIATOR, a phase IIb study of its ABT 450/r and ABT 267 and ABT 333 regimen for the treatment of Hepatitis C (HCV). The treatment demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all 8- and 12-week arms, with combinations of direct acting antivirals (DAAs) given with and without ribavirin (RBV). Results for the 12-week, triple-DAA regimen with ribavirin are as follows: SVR12 in treatment-na�ve genotype 1 (GT1) patients was 97.5 percent (77 of 79), and 93.3 percent (42 of 45) in GT1 null responder patients. In GT1a patients, SVR12 was achieved in 96 percent (52 of 54) of treatment na�ve patients and 89 percent (25 of 28) of null responder patients. In GT1b patients, SVR12 was achieved in 100 percent of treatment na�ve (25 of 25) and null responder patients (17 of 17).

Based on promising results from Aviator, Abbott has selected triple-DAA regimens, with and without ribavirin, to move forward into Phase III clinical trials. Results from the study were presented by Kris Kowdley, M.D., director of the Liver Center of Excellence in the Digestive Disease Institute at Virginia Mason Medical Center, at the Annual Meeting of the American Association for the Study of Liver Disease.